

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Bank of America, N.A.		10/26/2005	National Banking Association:

RECEIVING PARTY DATA

Name:	US Oral Pharmaceuticals Pty Ltd.
Street Address:	385 Bourke Street
Internal Address:	Level 24
City:	Melbourne
State/Country:	AUSTRALIA
Postal Code:	VIC 3000
Entity Type:	COMPANY: AUSTRALIA

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Registration Number:	0818177	ALCORUB
Registration Number:	2065489	KADIAN
Registration Number:	0836453	MOLECULON
Registration Number:	1192416	PUREBROM
Registration Number:	1785154	PUREPAC
Registration Number:	1801834	P
Registration Number:	0757619	
Registration Number:	0877237	SWEETASTE

CORRESPONDENCE DATA

Fax Number: (404)522-8409
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: (404) 420-5527
 Email: rbirdwell@phrd.com
 Correspondent Name: Rhonda J. Birdwell, Paralegal

CH \$215.00 0818177

Address Line 1: 285 Peachtree Center Avenue
Address Line 2: 1500 Marquis Two Tower
Address Line 4: Atlanta, GEORGIA 30303

ATTORNEY DOCKET NUMBER:

1809-43 ALPHARMA

DOMESTIC REPRESENTATIVE

Name:
Address Line 1:
Address Line 2:
Address Line 3:
Address Line 4:

NAME OF SUBMITTER:

Bobbi Acord

Signature:

/ba/

Date:

11/04/2005

Total Attachments: 7

source=IP Release 2#page1.tif
source=IP Release 2#page2.tif
source=IP Release 2#page3.tif
source=IP Release 2#page4.tif
source=IP Release 2#page5.tif
source=IP Release 2#page6.tif
source=IP Release 2#page7.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST (this "*Release*") is made as of October 26, 2005 (the "*Effective Date*"), by Bank of America, N.A., as collateral agent (the "*Collateral Agent*") for each of the Secured Parties (as defined in the Credit Agreement referred to below) in favor of US Oral Pharmaceuticals Pty Ltd., an Australian company, Purepac Pharmaceutical Co, a Delaware corporation, and Alharma Pharmaceuticals Inc. f/k/a Faulding Pharmaceuticals Inc., a Delaware corporation (collectively, "*Grantors*").

WHEREAS, pursuant to (i) that certain Credit Agreement dated as of October 5, 2001 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "*Credit Agreement*"), by and among Alharma Inc., Alharma Operating Corporation, Alharma USPD Inc., Alharma Pharmaceuticals Inc., Purepac Pharmaceutical Holdings, Inc., Purepac Pharmaceutical Co., Alharma Branded Products Division Inc., Collateral Agent, and the Lender Parties thereto, and (ii) that certain Security Agreement dated as of October 5, 2001, by and among the Grantors, certain other Persons named therein and the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the "*Security Agreement*"), each Grantor has granted to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors (capitalized terms used herein and not defined shall have the meanings assigned to such terms in the Credit Agreement);

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated January 3, 2002 (as amended, supplemented, amended and restated or otherwise modified from time to time, the "*IP Security Agreement*") by and among the Grantors and the Collateral Agent, each Grantor has granted to the Collateral Agent, for the ratable benefit for the Secured Parties, a security interest in all of the Grantors' right, title and interest in and to the Patents, Trademarks and Copyrights (as each term is defined in the IP Security Agreement);

WHEREAS, the IP Security Agreement was recorded on February 15, 2002 with the United States Patent and Trademark Office under reel and frame number 2455/0513 with respect to Trademarks;

WHEREAS, the IP Security Agreement was recorded on February 15, 2002 with the United States Patent and Trademark Office under reel and frame number 012631/0017 with respect to Patents;


WHEREAS, Collateral Agent has agreed to release its security interest in the Collateral (as defined in the IP Security Agreement) and assign, transfer, and grant all of its right, title and interest in the Collateral to Grantors;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Collateral Agent does hereby release and convey to the Grantors, without recourse, representation or warranty of any kind, the

Collateral Agent's security interest in and to each Grantor's right, title and interest in and to the Collateral, including the Collateral listed on Schedules A and B, granted pursuant to the Security Agreement and the IP Security Agreement.

IN WITNESS WHEREOF, Collateral Agent has caused this Release of Intellectual Property Security Interest to be duly executed as of the date above first written.

BANK OF AMERICA, N.A,
as Collateral Agent

By: 
Name: **JOSEPH L. CORAH**
Title: **SENIOR VICE PRESIDENT**

Schedule A

Schedule B to the IP Security Agreement

Trademarks

<u>Country</u>	<u>Trademark</u>	<u>Reg. No.</u>	<u>Reg. Date</u>	<u>Class</u>	<u>Owner</u>
United States	ALCORUB	0818177	November 8, 1966	5	Kalipharma, Inc. (n/k/a Purepac Pharmaceutical Co.)
United States	KADIAN	2065489	May 27, 1997	5	Mayne Health Logistics Pty Limited (n/k/a US Oral Pharmaceuticals Pty Ltd)
United States	MOLECULON	0836453	October 3, 1962	5	Moleculon, Inc. (n/k/a Faulding Pharmaceuticals Inc.)
United States	PUREBROM	1192,416	March 23, 1982	5	Kalipharma, Inc. (n/k/a Purepac Pharmaceutical Co.)
United States	PUREPAC	1785154	August 3, 1993	5	Purepac Pharmaceutical Co.
United States	Purepac Logo	1801834	November 2, 1993	5	Purepac Pharmaceutical Co.
United States	Purepac Logo	0757619	October 1, 1983	5	Kalipharma, Inc. (n/k/a Purepac Pharmaceutical Co.)
United States	SWEETASTE	0877237	September 16, 1969	5	Kalipharma, Inc. (n/k/a Purepac Pharmaceutical Co.)

Schedule B

List of Patents and Pending Patent Applications
Owned by Purepac or F.H. Faulding
Schedule A
to the IP Security Agreement

12/20/01

Patent Application No. Name of the Invention	Owner	Application Date	Application Status
US Application No. 09/606,629 Controlled Absorption Diltiazem Pharmaceutical Formulation	Purepac Pharmaceutical Co.	Jun. 29, 2000	Pending Application
US Application No. 09/873,994 A Pharmaceutical Tablet Formulation containing Gabapentin with Improved Physical and Chemical Characteristics and Method of Making the Same	Purepac Pharmaceutical Co.	Jun 6, 2001	Pending Application
International Application No. PCT/US00/23017 A Pharmaceutical Tablet Formulation containing Gabapentin with Improved Physical and chemical Characteristics and Method of Making the Same	Purepac Pharmaceutical Co.	Aug. 23, 2000	Pending Application
US Patent No. 6,294,198 A Pharmaceutical Tablet Formulation containing Gabapentin with Improved Physical and chemical Characteristics and Method of Making the Same	Purepac Pharmaceutical Co.	Aug. 21, 1999	Patent Expiration Date Aug. 21, 2019
US Provisional Application No. 60/284,181 A Sustained-Release Opioid Product That Achieves Peak-Opioid Plasma Concentrations Similar to an Immediate-Release Product	Not Assigned	Apr. 18, 2001	Pending Application
International Application No. PCT/US00/14049 A Pharmaceutical Composition Containing an Active Agent That Is Maintained in Solid Amorphous Form and Method of Making the Same	Purepac Pharmaceutical Co.	May 23, 2000	Pending Application
US Application No. 09/317,448 A Pharmaceutical Composition Containing an Active Agent That Is Maintained in Solid Amorphous Form and Method of Making the Same	Purepac Pharmaceutical Co.	May 24, 1999	Pending Application

TRADEMARK

REEL: 003188 FRAME: 0087

List of Patents and Pending Patent Applications
Owned by Purepac or F.H. Faulding Schedule A
to the IP Security Agreement

12/2001

US Patent No. 6,033,687 Controlled absorption diltiazem pharmaceutical formulation	Purepac Pharmaceutical Co.	Apr. 7, 1999	Patent Expiration Date Jan. 15, 2015
US Patent No. 5,834,024 Controlled absorption diltiazem pharmaceutical formulation	Purepac Pharmaceutical Co.	Mar. 10, 1997	Patent Expiration Date Jan. 15, 2015
US Patent No. 5,223,267 Analgesic compositions	Purepac Pharmaceutical Co.	Apr. 14, 1992	Patent Expiration Date July 29, 2010
US Patent No. 5,223,251 Skin fragrance compositions	Purepac Pharmaceutical Co.	Apr. 24, 1992	Patent Expiration Date Jun. 29, 2010

O:\Legal\Corporate\CORPFIGUREORGANIZATION\011217 List of Patents.doc